
Adalvo has acquired the romiplostim biosimilar programme referencing Nplate from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.
The transaction builds on Adalvo’s established capabilities in bringing complex pharmaceutical products to global markets and extends these capabilities into biologics. Beyond romiplostim, Adalvo is actively building a broader portfolio of biosimilar assets across the full value chain, from cell line development through to commercialisation.
For Adalvo’s global network of partners, this means access to a broader portfolio of technically complex medicines through the same integrated development, regulatory, supply and commercial platform. For Adalvo, it creates an additional engine for long-term growth in a strategically important segment of the pharmaceutical market.
The acquired programme references Nplate (romiplostim), a treatment indicated for adult and chronic paediatric immune thrombocytopenia (ITP).
Developed using microbial cell line technology, the programme represents a technically sophisticated biosimilar opportunity aligned with Adalvo’s focus on high-value, complex medicines.
With the reference product generating approximately US$ 1.5 billion in global sales in 2025, the programme represents a significant global opportunity and supports Adalvo’s ambition to broaden access to high-quality biological medicines across international markets.
For Enzene, the transaction marks a strategic inflection point. Having built an integrated biosimilar platform spanning cell line development, process development, clinical supply and commercial manufacturing, Enzene is now a global biosimilar CDMO of choice, focusing its business model fully on contract development and manufacturing services for biologics.
Enzene will continue to serve as development and manufacturing partner to Adalvo for the romiplostim programme, including support for regulatory filings with the US FDA, the European Medicines Agency and other international regulatory authorities, and will supply the product from its GMP-approved facilities in Pune, India.
The partnership with Adalvo marks a significant step in Enzene’s transition of its biosimilar pipeline to commercial partners, while expanding its CDMO offering to global biopharmaceutical companies.


